James J. Vaughn Sells 4,500 Shares of Genomic Health, Inc. (NASDAQ:GHDX) Stock

Share on StockTwits

Genomic Health, Inc. (NASDAQ:GHDX) insider James J. Vaughn sold 4,500 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $57.09, for a total transaction of $256,905.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

James J. Vaughn also recently made the following trade(s):

  • On Thursday, June 6th, James J. Vaughn sold 8,745 shares of Genomic Health stock. The shares were sold at an average price of $52.47, for a total transaction of $458,850.15.

Shares of GHDX stock opened at $56.20 on Friday. Genomic Health, Inc. has a 52-week low of $50.77 and a 52-week high of $92.18. The company has a market capitalization of $2.14 billion, a PE ratio of 53.52 and a beta of 1.07. The company has a current ratio of 5.67, a quick ratio of 5.67 and a debt-to-equity ratio of 0.19. The firm has a 50 day simple moving average of $54.75.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Tuesday, May 7th. The medical research company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.05. Genomic Health had a net margin of 10.35% and a return on equity of 18.70%. The firm had revenue of $108.80 million for the quarter, compared to analysts’ expectations of $106.75 million. During the same period last year, the firm earned ($0.11) earnings per share. The business’s revenue for the quarter was up 17.5% on a year-over-year basis. As a group, analysts forecast that Genomic Health, Inc. will post 1.46 EPS for the current year.

A number of equities analysts have issued reports on GHDX shares. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Beigene in a research note on Thursday, June 20th. Needham & Company LLC set a $69.00 price objective on shares of Genomic Health and gave the company a “buy” rating in a research note on Wednesday, June 19th. Canaccord Genuity raised their price objective on shares of ServiceNow from $285.00 to $300.00 and gave the company a “buy” rating in a research note on Wednesday, May 8th. Deutsche Bank set a $18.00 price objective on shares of Commercial Metals and gave the company a “buy” rating in a research note on Thursday, May 30th. Finally, BidaskClub raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 4th. Eight analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $64.86.

Several hedge funds and other institutional investors have recently made changes to their positions in GHDX. Norges Bank bought a new position in shares of Genomic Health during the fourth quarter worth $20,975,000. Fiera Capital Corp bought a new position in shares of Genomic Health during the first quarter worth $20,134,000. FMR LLC boosted its position in shares of Genomic Health by 83.8% during the fourth quarter. FMR LLC now owns 550,627 shares of the medical research company’s stock worth $35,466,000 after purchasing an additional 251,085 shares in the last quarter. Two Sigma Investments LP boosted its position in shares of Genomic Health by 1,336.7% during the fourth quarter. Two Sigma Investments LP now owns 209,592 shares of the medical research company’s stock worth $13,500,000 after purchasing an additional 195,004 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in shares of Genomic Health by 269.2% during the first quarter. Assenagon Asset Management S.A. now owns 267,410 shares of the medical research company’s stock worth $18,732,000 after purchasing an additional 194,988 shares in the last quarter. 95.54% of the stock is currently owned by institutional investors.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Featured Story: Outperform Rating

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Selfkey   Trading 1.9% Lower  Over Last 7 Days
Selfkey Trading 1.9% Lower Over Last 7 Days
Devery Price Hits $0.0037 on Top Exchanges
Devery Price Hits $0.0037 on Top Exchanges
DMarket Tops 1-Day Trading Volume of $192,028.00
DMarket Tops 1-Day Trading Volume of $192,028.00
Insider Buying: Covetrus Inc  Insider Buys 1,684 Shares of Stock
Insider Buying: Covetrus Inc Insider Buys 1,684 Shares of Stock
Recent Investment Analysts’ Ratings Changes for Admiral Group
Recent Investment Analysts’ Ratings Changes for Admiral Group
Verint Systems  Downgraded by Zacks Investment Research to “Hold”
Verint Systems Downgraded by Zacks Investment Research to “Hold”


 
© 2006-2019 Zolmax.